Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.
Steven E. Coutre
Research Funding - Gilead Sciences
Richard R. Furman
Research Funding - Gilead Sciences
Jeff Porter Sharman
Research Funding - Gilead Sciences
Bruce D. Cheson
Research Funding - Gilead Sciences
John M. Pagel
Research Funding - Gilead Sciences
Peter Hillmen
Research Funding - Gilead Sciences
Jacqueline Claudia Barrientos
Research Funding - Gilead Sciences
Andrew David Zelenetz
Research Funding - Gilead Sciences
Thomas J. Kipps
Research Funding - Gilead Sciences
Ian Flinn
Research Funding - Gilead Sciences
Paolo Ghia
Research Funding - Gilead Sciences
Herbert Aaron Eradat
Research Funding - Gilead Sciences
Thomas J. Ervin
Research Funding - Gilead Sciences
Nicole Lamanna
Research Funding - Gilead Sciences
Bertrand Coiffier
Research Funding - Gilead Sciences
Andrew Pettitt
Research Funding - Gilead Sciences
Yeonhee Kim
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Thomas Michael Jahn
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Susan Mary O'Brien
Research Funding - Gilead Sciences
Michael J. Hallek
Research Funding - Gilead Sciences